NCT00519662

Safety and Tolerability Study of SNS-314 for Advanced Solid Tumors

Phase 1 Open-Label Multicenter, Dose-Escalating, Clinical Study of the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Profiles of SNS-314, a Novel Aurora Kinase Inhibitor, Administered to Patients With Advanced Solid Tumors

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 32 (actual)
• Sponsor: Sunesis Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a study to assess the safety and tolerability of SNS-314 in advanced solid tumors in humans.

Detailed description

Other objectives of this study include measuring pharmacokinetics (how long the drug can be measured in the blood).

Conditions

• Advanced Solid Tumors

Interventions

Type	Name	Description
DRUG	SNS-314	Stage 1 - Escalating doses of SNS-314 Injection on days 1, 8 and 15 Stage 2 - Same as stage 1 except SNS-314 Injection is administered at the maximum tolerated dose established in stage 1

Timeline

• Start date: 2007-08-01
• Primary completion: 2009-03-01
• Completion: 2009-03-01
• First posted: 2007-08-22
• Last updated: 2017-04-04

Locations

4 sites across 1 country: United States